Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

Bibliography

• Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007;10:1-12
   Google Scholar
• De Pauw BE. Increasing fungal infections in the intensive care unit. Surg Infect (Larchmt) 2006;7(Suppl 2):S93-6
   PubMedGoogle Scholar
• Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6
   PubMed Web of Science ®Google Scholar
• Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506
   PubMed Web of Science ®Google Scholar
• Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002;17:168-75
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9
   PubMed Web of Science ®Google Scholar
• Fridkin SK. Candidemia is costly-plain and simple. Clin Infect Dis 2005;41:1240-1
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Chu JH, Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006;117:e711-16
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K, Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Peman J, Bernhardt H, Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-22
   PubMed Web of Science ®Google Scholar
• Morgan J, Meltzer MI, Plikaytis BD, Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7
   PubMed Web of Science ®Google Scholar
• Horn DL, Fishman JA, Steinbach WJ, Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007;59:407-14
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A, Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30
   PubMed Web of Science ®Google Scholar
• Sobel JD. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep 2006;8:427-33
   PubMedGoogle Scholar
• Ullmann AJ, Sanz MA, Tramarin A, Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006;43:e29-38
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Penzak SR, Polston S, Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002;22:961-71
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93
   PubMed Web of Science ®Google Scholar
• Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect Ther 2005;3:167-81
   PubMedGoogle Scholar
• Cornely OA, Sidhu M, Odeyemi I, Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24:1743-53
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G, Micafungin versus liposomal amphotericin B for pediatric patients with invasive Candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16
   PubMed Web of Science ®Google Scholar
• de Wet NT, Bester AJ, Viljoen JJ, A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005;21:899-907
   PubMed Web of Science ®Google Scholar
• Mycamine: Summary of product characteristics. Astellas Pharma GmbH. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/emea-combined-h734en.pdf [Last accessed 8 July 2010]
   Google Scholar
• Mycamine® (micafungin sodium) for injection: Prescribing Information. Astellas Pharma US, Inc., January 2008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021506s008lbl.pdf [Last accessed 8 July 2010]
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51
   PubMed Web of Science ®Google Scholar
• Tamura K, Urabe A, Yoshida M, Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009;50:92-100
   PubMed Web of Science ®Google Scholar
• EraxisTM (anidulafungin) for injection: Prescribing Information. Pfizer Inc, June 2009. Available from: http://media.pfizer.com/files/products/uspi_eraxis.pdf [Last accessed 8 July 2010]
   Google Scholar
• Cancidas® (caspofungin acetate): Prescribing Information. Merck & Co., Inc., February 2010. Available from: http://www.merck.com/product/usa/pi_circulars/c/cancidas/cancidas_pi.pdf [Last accessed 8 July 2010]
   Google Scholar
• Vfend® (voriconazole): prescribing Information. Pfizer, Inc, June 2010. Available from: http://www.pfizer.com/files/products/uspi_vfend.pdf [Last accessed 8 July 2010]
   Google Scholar
• Diflucan® (fluconazole): Prescribing Information. Pfizer Inc, January 2010. Available from: http://media.pfizer.com/files/products/uspi_diflucan.pdf [Last accessed 8 July 2010]
   Google Scholar
• Buell DN, Kovanda L, Drake T, Fisco C. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Abstract M-719. Presented at the 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC); 16 – 19 December 2005; Washington DC, USA
   Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61
   PubMed Web of Science ®Google Scholar
• Kohno S, Masaoka T, Yamaguchi H, A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-9
   PubMed Web of Science ®Google Scholar
• de Wet N, Llanos-Cuentas A, Suleiman J, A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9
   PubMed Web of Science ®Google Scholar
• Pettengell K, Mynhardt J, Kluyts T, Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475-81
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49:1331-6
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R, A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38:47-51
   PubMed Web of Science ®Google Scholar
• Heresi GP, Gerstmann DR, Reed MD, The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-15
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24
   PubMed Web of Science ®Google Scholar